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OBJECTIVES: The main purpose was to describe calcium
channel blocker (CCB) utilization in hypertensive patients in the
Louisiana Medicaid Program. To accomplish this purpose two
objectives were formulated: 1) To determine if there were sig-
niﬁcant demographic differences by type of CCB or prescribing
physician specialty, and 2) To determine treatment compliance
including the medication possession ratio (MPR), drug switch-
ing, dose changes, and discontinuation of therapy. METHODS:
A retrospective analysis using paid Louisiana Medicaid claims
was performed. The index date was the date of service of the
ﬁrst paid claim with a primary or secondary diagnosis of hyper-
tension between July 1, 2003 and June 30, 2004. Recipient study
period was index date plus 365 days preceded by a 6-month
washout period. Inclusion criteria were: 18 to 64 years old, at
least one CCB during the study period, eligible at least 11 months
in study period and during washout. Exclusion criteria were end-
stage renal disease and hypertension due to pregnancy. For
Objective 1, a chi-square test was performed to determine if there
were signiﬁcant demographic differences by CCB and prescrib-
ing physician specialty. For Objective 2, a “compliant” patient
was deﬁned as a patient with an MPR °Y´ 80%. A switch was
deﬁned as a change in prescription medication within CCBs.
Dose change was deﬁned as change in strength or quantity for
the same CCB. RESULTS: The ﬁnal dataset contained 2493
patients. The majority (41%) used amlodipine, followed by
nifedipine (19.74), diltiazem (15.48%), felodipine (10.31%),
verapamil (7.9%), nisoldipine (5.21%), isradipine (0.36%), and
nicardipine (0.08%). Cardiologist accounted for 18.41% of the
prescribing physician. Average days to discontinuation were 262
days. Compliance was met by 59% of the patients. Therapy
switch occurred 11% of the time; dose changes, 37% of the time.
CONCLUSION: CCB utilization results match the literature,
although specialist utilization is low.
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OBJECTIVES: Clinical guidelines recommend long-term use of
beta-blockers (BB), statins, and angiotensin converting enzyme-
inhibitors or angiotensin receptor blockers (ACEI/ARB) after
myocardial infarction (MI). Previous studies have evaluated their
use during the MI hospitalization, but data on their use after 
discharge are scarce. METHODS: From the claims data of 8
sickness funds insuring >50% of the Austrian population, we
ascertained all patients discharged with a primary diagnosis of
acute MI in 2004. We only included patients who were hospi-
talized for °Y´4 days and who survived 120 days. We ascertained
use of ACEI/ARBs, BBs, and statins from all ﬁlled prescriptions
between discharge and 120 days post MI. Demographics were
noted for each patient and comorbidities were ascertained from
use of several indicator drugs during the preceding year. Multi-
variate logistic regression was used to evaluate the independent
determinants of use of each drug class. RESULTS: We evaluated
4105 patients with MI. The mean age was 68.8 (¿À13.2) years
and 59.5% were men. The mean length of stay for their index
admission was 10.9 (¿À5.3) days. Within 120 days of MI, 67%
ﬁlled a prescription for an ACE/ARB, 74% for a BB, and 67%
for a statin. While 41% received all three drugs and 34% two
of these, 25% of patients received only one or none of the study
drugs. Older age and presence of mental illness was associated
with lower use of all drug classes. Diabetics had greater
ACEI/ARB use. BB were more common in patients using other
antihypertensives, but less frequent in patients with inhaled
steroids or beta-mimetics. Statins use was less in patients using
drugs for congestive heart failure (coumadin, diuretics, digitalis;
(all P < 0.001). CONCLUSION: Recommended medications
were underused in Austrian MI survivors. Quality indicators
should be established and interventions be implemented to
ensure maximum secondary prevention of coronary heart disease
in this population.
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OBJECTIVES: Treatment guidelines recommending clopidogrel
use in acute coronary syndrome (ACS) have rapidly evolved since
2000. The goal of this study was to examine persistence of clopi-
dogrel in ACS patients in order to establish a baseline for later
comparisons. METHODS: Administrative claims data from a
large US health plan (from January 1, 2001–June 30, 2003) were
used to identify ACS patients by ICD-9 codes for unstable angina
or acute myocardial infarction (MI). The ﬁrst diagnosis claim
was the “index event.” Patients were grouped according to
receipt of percutaneous coronary intervention (PCI) or not
during the index event, and secondly, if they received clopido-
grel for >30 days in duration after discharge. Characteristics
associated with >30 days clopidogrel use was examined by logis-
tic regression. Patients were observed 1-year before, and fol-
lowed up to 1-year after, the index event. RESULTS: There were
4385 patients who underwent PCI; 2698 received clopidogrel for
>30 days duration (61.5%). There were 935 patients who did
not receive PCI; 279 received clopidogrel for >30 days duration
(29.8%). In PCI patients, prior use of clopidogrel (OR; 95% CI)
(2.023; 1.045–3.916) and cost of index MI (1.407; 1.231–1.608)
had the largest positive association with >30 days clopidogrel
use. Patients with ﬁbrositis, myalgia and arthralgia were least
likely to have >30 days duration of clopidogrel therapy. In non-
PCI patients, prior use of clopidogrel (5.599; 2.229–14.063) and
hospitalization with the index event (1.949; 1.181–3.218) had
the largest positive association with >30 days clopidogrel use.
Patients residing in the Northeast US were least likely to have
>30 days duration of clopidogrel therapy. CONCLUSION:
During this time period, clopidogrel was used more frequently
and for longer duration in PCI patients. There were few observ-
able predictors of longer duration of therapy. The single
strongest predictor of use for >30 days after an ACS event was
clopidogrel use in the baseline period.
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OBJECTIVES: To explore whether Medicaid preferred drug lists
(PDL) impact the utilization of restricted statin medications for
Medicaid patients equally, or disproportionately impact patients
treated by doctors prescribing in poor or minority neighbor-
hoods. METHODS: A retrospective, regression-based analysis,
of a pharmacy claims database and census data of the pre-
scriber’s zip-code. Post policy changes in the proportion of statin
prescriptions ﬁlled for off-PDL medicines were examined in six
